Expansion platform type II: testing a treatment strategy.
作者信息
Catenacci Daniel V T
机构信息
Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA.
出版信息
Lancet Oncol. 2015 Oct;16(13):1276-8. doi: 10.1016/S1470-2045(15)00224-7. Epub 2015 Sep 3.
Abstract
摘要
相似文献
1
Expansion platform type II: testing a treatment strategy.
Lancet Oncol. 2015 Oct;16(13):1276-8. doi: 10.1016/S1470-2045(15)00224-7. Epub 2015 Sep 3.
2
Precision medicine: lessons learned from the SHIVA trial.
Lancet Oncol. 2015 Dec;16(16):e580. doi: 10.1016/S1470-2045(15)00387-3.
3
Precision medicine: lessons learned from the SHIVA trial.
Lancet Oncol. 2015 Dec;16(16):e580-1. doi: 10.1016/S1470-2045(15)00458-1.
4
Precision medicine: lessons learned from the SHIVA trial.
Lancet Oncol. 2015 Dec;16(16):e579-80. doi: 10.1016/S1470-2045(15)00397-6.
5
Precision medicine: lessons learned from the SHIVA trial - Authors' reply.
Lancet Oncol. 2015 Dec;16(16):e581-2. doi: 10.1016/S1470-2045(15)00455-6.
6
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3.
7
The Future of Precision Oncology for the Treatment of Solid Tumors.
Clin Pharmacol Ther. 2020 Sep;108(3):416-418. doi: 10.1002/cpt.1739. Epub 2020 Jan 25.
8
Lack of access to targeted cancer therapy.
Lancet Oncol. 2015 Oct;16(13):e482. doi: 10.1016/S1470-2045(15)00274-0. Epub 2015 Aug 28.
9
Evidence-Based Development and Clinical Use of Precision Oncology Therapeutics.
Clin Pharmacol Ther. 2020 Sep;108(3):440-443. doi: 10.1002/cpt.1967. Epub 2020 Aug 3.
10
Personalising the treatment of prostate cancer.
Lancet Oncol. 2015 Dec;16(16):e592. doi: 10.1016/S1470-2045(15)00474-X. Epub 2015 Nov 6.
引用本文的文献
1
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease.
Cancer Discov. 2021 Feb;11(2):308-325. doi: 10.1158/2159-8290.CD-20-1408. Epub 2020 Nov 24.
2
Specifying the True- and False-Positive Rates in Basket Trials.
JCO Precis Oncol. 2017 Nov 3;1. doi: 10.1200/PO.17.00181. eCollection 2017.
3
When Inhibitor MET Biomarker: Postmortem or Initium Novum?
JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00359. Epub 2019 Mar 8.
4
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for -Amplified Gastroesophageal Adenocarcinoma.
Cancer Discov. 2018 Jun;8(6):696-713. doi: 10.1158/2159-8290.CD-17-1260. Epub 2018 Feb 15.
5
Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.
Cancer Discov. 2018 Jan;8(1):37-48. doi: 10.1158/2159-8290.CD-17-0395. Epub 2017 Oct 4.
6
Clinical Trials in the Genomic Era.
J Clin Oncol. 2017 Mar 20;35(9):1011-1017. doi: 10.1200/JCO.2016.70.8891. Epub 2017 Feb 13.
7
Novel Targeted Therapies for Esophagogastric Cancer.
Surg Oncol Clin N Am. 2017 Apr;26(2):293-312. doi: 10.1016/j.soc.2016.10.002.
8
Precision medicine needs randomized clinical trials.
Nat Rev Clin Oncol. 2017 May;14(5):317-323. doi: 10.1038/nrclinonc.2017.8. Epub 2017 Feb 7.
本文引用的文献
1
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Lancet Oncol. 2015 Oct;16(13):1324-34. doi: 10.1016/S1470-2045(15)00188-6. Epub 2015 Sep 3.
2
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
J Clin Oncol. 2015 Mar 20;33(9):1000-7. doi: 10.1200/JCO.2014.58.2007. Epub 2015 Feb 9.
3
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.
Mol Oncol. 2015 May;9(5):967-96. doi: 10.1016/j.molonc.2014.09.011. Epub 2014 Oct 18.
4
Next-generation companion diagnostics: promises, challenges, and solutions.
Arch Pathol Lab Med. 2015 Jan;139(1):11-3. doi: 10.5858/arpa.2014-0063-ED.
5
National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Am Soc Clin Oncol Educ Book. 2014:71-6. doi: 10.14694/EdBook_AM.2014.34.71.
6
Evaluating many treatments and biomarkers in oncology: a new design.
J Clin Oncol. 2013 Dec 20;31(36):4562-8. doi: 10.1200/JCO.2013.50.7905. Epub 2013 Nov 18.
Zotero 插件